SCHEMBL29415420

SCHEMBL29415420

Fc1ccc(Oc2ccncn2)cc1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 2/20 0.51
KMT2A Q03164 2/20 0.51
KDM4E B2RXH2 1/20 0.51
HSPB1 P04792 2/20 0.49
L3MBTL1 Q9Y468 3/20 0.47
ALDH1A1 P00352 1/20 0.47
HTT P42858 2/20 0.45
MAPK14 Q16539 2/20 0.44
BRAF P15056 1/20 0.44
KDR P35968 1/20 0.44
TNNI3K Q59H18 1/20 0.44
CA12 O43570 1/20 0.41
CA1 P00915 1/20 0.41
CA2 P00918 1/20 0.41
CA9 Q16790 1/20 0.41
MGAT2 Q10469 1/20 0.39
MAPT P10636 2/20 0.39
LMNA P02545 1/20 0.39
SCN4A P35499 1/20 0.39
TRPA1 O75762 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL169685 0.81 MEN1 (0.53) MEN1KMT2AKDM4EALDH1A1HTT
SCHEMBL1895117 0.81 MEN1 (0.50) MEN1KMT2AKDM4EALDH1A1MAPK14
SCHEMBL6691249 0.81 KDR (0.49) MEN1KMT2AL3MBTL1HTTMAPK14
SCHEMBL1136337 0.80 SMN1; SMN2 (0.50) L3MBTL1ALDH1A1HTTMAPK14BRAF
SCHEMBL11196649 0.79 HSP90AA1 (0.46) MAPK14BRAFKDRTNNI3KMAPT
SCHEMBL12261855 0.77 KDR (0.39) MEN1KMT2AMAPK14BRAFKDR
SCHEMBL6329262 0.77 CYP2D6 (0.55) MEN1KMT2AKDM4EHSPB1L3MBTL1
SCHEMBL10033144 0.77 RAB9A (0.55) MEN1KMT2AKDM4EALDH1A1HTT
SCHEMBL27445864 0.76 KDR (0.41) KDM4EMAPK14BRAFKDRTNNI3K
SCHEMBL18575400 0.76 KDR (0.44) MEN1KMT2AKDM4EHSPB1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220073508-A1 GLUCOSYLCERAMIDE SYNTHASE INHIBITORS GENZYME CORPORATION (US) 2022-03-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220073508-A1 GLUCOSYLCERAMIDE SYNTHASE INHIBITORS GBA1, GBA2, GAA MEN1 1532/4885KMT2A 2721/4885KDM4E 4241/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.